CareDx Acquires Naveris for $35M Revenue Oncology Test
Event summary
- CareDx completed its acquisition of Naveris on July 1, 2026.
- Naveris’s lead product, NavDx, is a blood-based test for viral-mediated cancers with $35M revenue in 2025.
- NavDx has an ADLT Medicare reimbursement rate of $1,800 and over 130,000 tests commercially reported to date.
- CareDx now offers diagnostics across transplant, cell therapy, and viral-mediated cancers in a $12B U.S. market.
The big picture
CareDx’s acquisition of Naveris extends its precision medicine diagnostics leadership into high-growth specialty oncology, complementing its existing transplant and cell therapy offerings. The deal underscores the increasing convergence of molecular biomarker testing across chronic disease states, particularly where longitudinal monitoring drives repeat testing revenue.
What we're watching
- Revenue Integration
- How CareDx will scale Naveris’s $35M revenue stream within its existing portfolio.
- Market Penetration
- Whether NavDx can expand beyond Medicare-covered HPV-driven cancers into other viral-mediated oncology segments.
- Execution Risk
- The pace at which CareDx can integrate Naveris’s technology and commercial operations without disrupting existing diagnostics businesses.
Related topics